Creotech Instruments First Quarter 2025 Earnings: EPS: zł0.59 (vs zł1.40 loss in 1Q 2024)

Simply Wall St

Creotech Instruments (WSE:CRI) First Quarter 2025 Results

Key Financial Results

  • Revenue: zł25.5m (up 191% from 1Q 2024).
  • Net income: zł1.40m (up from zł3.33m loss in 1Q 2024).
  • Profit margin: 5.5% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
  • EPS: zł0.59 (up from zł1.40 loss in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

WSE:CRI Earnings and Revenue History June 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Creotech Instruments shares are down 1.3% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Creotech Instruments you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Creotech Instruments might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.